We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adient (ADNT) Earnings Lag Estimates in Q2, Shares Decline
Read MoreHide Full Article
Shares of Adient plc (ADNT - Free Report) declined roughly 9.8% in a day’s trading, following the second-quarter fiscal 2019 earnings release on May 7. In the reported quarter, the company’s adjusted earnings per share were 31 cents, missing the Zacks Consensus Estimate of 39 cents. The adjusted bottom-line figure in the year-ago quarter was $1.82 per share.
Reportedly, quarterly net loss attributable to Adient was $149 million compared with net loss of $168 million in the prior-year quarter.
During the quarter under review, the company reported net sales of $4.23 billion, marking a decline from $4.6 billion recorded in second-quarter fiscal 2018. However, the top line surpassed the Zacks Consensus Estimate of $4.12 billion.
During the reported quarter, Adient’s Seating and Seat Structures & Mechanisms (SS&M) segment’s net sales were $1.92 billion, down from $2.3 billion in second-quarter fiscal 2018. Further, the Interior segment reported net sales of $1.94 billion, down from $2.3 billion in the prior-year quarter.
Segment Results
During the second quarter, the company realigned its organizational structure to manage business on the basis of geographical regions. The three reportable segments Adient currently operates are Americas, which includes North America and South America; Europe, Middle East, and Africa ('EMEA"); and Asia Pacific/China ("Asia").
In the Americas, the company generated adjusted EBITDA of $34 million in second-quarter fiscal 2019 compared with $98 million recorded in the prior-year quarter. This plunge was due to lower volume and mix along with increased SG&A and product launch costs.
In EMEA, Adient’s quarterly adjusted EBITDA was $59 million compared with $130 million in the prior-year quarter. The plunge was due to lower volume, negative impact of foreign currencies and product launch inefficiencies.
In Asia, the company’s quarterly adjusted EBITDA was $123 million compared with $157 million in the second quarter of fiscal 2018. This decline was due to lower volume and equity income.
Financials
Adient had cash and cash equivalents of $491 million as of Mar 31, 2019, compared with $687 million as of Sep 30, 2018. As of the same date, net debt amounted to $2.9 billion, up from $2.7 billion as of Sep 30, 2018.
In the second quarter, cash inflow by operating activities was $168 million against an outflow of $23 million in the same period of fiscal 2018. Capital expenditure declined to $108 million from $123 million recorded in the prior-year quarter.
Gentex has an expected long-term growth rate of 6%. The stock has gained 18.1% in the past three months.
Oshkosh has an expected long-term growth rate of 11.6%. The stock has gained 3.3% in the past three months.
Ford has an expected long-term growth rate of 8.1%. Over the past three months, shares of the company have gained 23.7%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Adient (ADNT) Earnings Lag Estimates in Q2, Shares Decline
Shares of Adient plc (ADNT - Free Report) declined roughly 9.8% in a day’s trading, following the second-quarter fiscal 2019 earnings release on May 7. In the reported quarter, the company’s adjusted earnings per share were 31 cents, missing the Zacks Consensus Estimate of 39 cents. The adjusted bottom-line figure in the year-ago quarter was $1.82 per share.
Reportedly, quarterly net loss attributable to Adient was $149 million compared with net loss of $168 million in the prior-year quarter.
During the quarter under review, the company reported net sales of $4.23 billion, marking a decline from $4.6 billion recorded in second-quarter fiscal 2018. However, the top line surpassed the Zacks Consensus Estimate of $4.12 billion.
Adient PLC Price, Consensus and EPS Surprise
Adient PLC Price, Consensus and EPS Surprise | Adient PLC Quote
During the reported quarter, Adient’s Seating and Seat Structures & Mechanisms (SS&M) segment’s net sales were $1.92 billion, down from $2.3 billion in second-quarter fiscal 2018. Further, the Interior segment reported net sales of $1.94 billion, down from $2.3 billion in the prior-year quarter.
Segment Results
During the second quarter, the company realigned its organizational structure to manage business on the basis of geographical regions. The three reportable segments Adient currently operates are Americas, which includes North America and South America; Europe, Middle East, and Africa ('EMEA"); and Asia Pacific/China ("Asia").
In the Americas, the company generated adjusted EBITDA of $34 million in second-quarter fiscal 2019 compared with $98 million recorded in the prior-year quarter. This plunge was due to lower volume and mix along with increased SG&A and product launch costs.
In EMEA, Adient’s quarterly adjusted EBITDA was $59 million compared with $130 million in the prior-year quarter. The plunge was due to lower volume, negative impact of foreign currencies and product launch inefficiencies.
In Asia, the company’s quarterly adjusted EBITDA was $123 million compared with $157 million in the second quarter of fiscal 2018. This decline was due to lower volume and equity income.
Financials
Adient had cash and cash equivalents of $491 million as of Mar 31, 2019, compared with $687 million as of Sep 30, 2018. As of the same date, net debt amounted to $2.9 billion, up from $2.7 billion as of Sep 30, 2018.
In the second quarter, cash inflow by operating activities was $168 million against an outflow of $23 million in the same period of fiscal 2018. Capital expenditure declined to $108 million from $123 million recorded in the prior-year quarter.
Zacks Rank & Stocks to Consider
Adient currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader auto sector are Gentex Corporation (GNTX - Free Report) , Oshkosh Corporation (OSK - Free Report) and Ford Motor Company (F - Free Report) , each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Gentex has an expected long-term growth rate of 6%. The stock has gained 18.1% in the past three months.
Oshkosh has an expected long-term growth rate of 11.6%. The stock has gained 3.3% in the past three months.
Ford has an expected long-term growth rate of 8.1%. Over the past three months, shares of the company have gained 23.7%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>